Wenbin Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenbin Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Jiangxin Yang
3 shared publicationsYanpeng Cao
3 shared publicationsRui Liang
2 shared publications- Yanlong Cao
Zhejiang University
2 shared publications Amanda Casper
Departments of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR, 97239, USA
1 shared publication- Bowen Zhao
Zhejiang University
1 shared publication
Latest Publications
- Open Access
- 28 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10765
Visualizing intraorganellar ultrastructures, dynamics, and interactions with open-access background-free Lock-in-SIM
Structured illumination microscopy (SIM) is a powerful method for fast and gentle live-cell super-resolution imaging. However, its susceptibility to reconstruction artifacts from out-of-focus blur and background imposes substantial barriers to analyze the dynamics of densely packed volumetric intraorganellar ultrastructures that are typically in a size range of SIM’s spatial resolution. To address this limitation, we have developed Lock-in-SIM, an open-access two-dimensional SIM framework that eliminates background and maximizes the recovery of sub-diffraction information with the highest possible frequency extraction. By leveraging the intrinsic modulation differences of volumetric sample structures, Lock-in-SIM enables efficient optical sectioning, extends imaging depth, and improves data fidelity and quantifiability. We demonstrate the superiority of Lock-in-SIM by visualizing various challenging intraorganellar ultrastructures in live cells. Our investigations uncover mechanisms of mitochondrial fission and endoplasmic reticulum-lysosome interactions and provide insights into the intricate yet highly regulated structural remodeling of organelles.
- 28 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10765
Open AccessVisualizing intraorganellar ultrastructures, dynamics, and interactions with open-access background-free Lock-in-SIM
Structured illumination microscopy (SIM) is a powerful method for fast and gentle live-cell super-resolution imaging. However, its susceptibility to reconstruction artifacts from out-of-focus blur and background imposes substantial barriers to analyze the dynamics of densely packed volumetric intraorganellar ultrastructures that are typically in a size range of SIM’s spatial resolution. To address this limitation, we have developed Lock-in-SIM, an open-access two-dimensional SIM framework that eliminates background and maximizes the recovery of sub-diffraction information with the highest possible frequency extraction. By leveraging the intrinsic modulation differences of volumetric sample structures, Lock-in-SIM enables efficient optical sectioning, extends imaging depth, and improves data fidelity and quantifiability. We demonstrate the superiority of Lock-in-SIM by visualizing various challenging intraorganellar ultrastructures in live cells. Our investigations uncover mechanisms of mitochondrial fission and endoplasmic reticulum-lysosome interactions and provide insights into the intricate yet highly regulated structural remodeling of organelles.
- 6 March 2023
- Published by Elsevier in Engineering Applications of Artificial Intelligence
- Vol. 122
A sub-region Unet for weak defects segmentation with global information and mask-aware loss
- 6 March 2023
- Published by Elsevier in Engineering Applications of Artificial Intelligence
- Vol. 122
A sub-region Unet for weak defects segmentation with global information and mask-aware loss
- 11 November 2022
- Published by Elsevier in Optics and Lasers in Engineering
- Vol. 161
Dynamic-excitation-based steady-state non-line-of-sight imaging via multi-branch convolutional neural network
- 11 November 2022
- Published by Elsevier in Optics and Lasers in Engineering
- Vol. 161
Dynamic-excitation-based steady-state non-line-of-sight imaging via multi-branch convolutional neural network
- 17 October 2022
- Published by Elsevier in Optics and Lasers in Engineering
- Vol. 161
An effective industrial defect classification method under the few-shot setting via two-stream training
- 17 October 2022
- Published by Elsevier in Optics and Lasers in Engineering
- Vol. 161
An effective industrial defect classification method under the few-shot setting via two-stream training
- Open Access
- 2 October 2014
- Published by Springer Nature in Translational Stroke Research
- Vol. 6 (1) , 60-68
Preclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke
Recombinant T cell Receptor Ligand 1000 (RTL1000), a partial human major histocompatibility complex (MHC) molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DRB1*1502 transgenic (DR2-Tg) mice. In this study, we characterized the therapeutic time window of opportunity for RTL1000; we explored the efficacy of a single dose of RTL1000 administration and determined if RTL1000 affords long-term neurobehavioral functional improvement after ischemic stroke. Male DR2-Tg mice underwent 60 min of intraluminal reversible middle cerebral artery occlusion (MCAO). RTL1000 or vehicle was injected 4, 6, or 8 h after MCAO, followed by three daily injections. In the single-dose study, one-time injection of RTL1000 was applied 4 h after MCAO. Cortical, striatal, and hemispheric infarct sizes were measured 24 or 96 h after stroke. Behavioral testing, including neuroscore evaluation, open field, paw preference, and novel object recognition, was performed up to 28 days after stroke. Our data showed that RTL1000 significantly reduced the infarct size 96 h after MCAO when the first injection was given at 4 and 6 h, but not 8 h, after the onset of stroke. A single dose of 400 or 100 μg RTL1000 also significantly reduced the infarct size 24 h after MCAO. Behavioral testing showed that RTL1000 treatment used 4 h after MCAO improved long-term cognitive outcome 28 days after stroke. Taken together, RTL1000 protects against acute injury if applied within a 6-h time window and improves long-term functional recovery after experimental stroke in DR2-Tg mice.
- 2 October 2014
- Published by Springer Nature in Translational Stroke Research
- Vol. 6 (1) , 60-68
Open AccessPreclinical Evaluation of Recombinant T Cell Receptor Ligand RTL1000 as a Therapeutic Agent in Ischemic Stroke
Recombinant T cell Receptor Ligand 1000 (RTL1000), a partial human major histocompatibility complex (MHC) molecule coupled to a human myelin peptide, reduces infarct size after experimental stroke in HLA-DRB1*1502 transgenic (DR2-Tg) mice. In this study, we characterized the therapeutic time window of opportunity for RTL1000; we explored the efficacy of a single dose of RTL1000 administration and determined if RTL1000 affords long-term neurobehavioral functional improvement after ischemic stroke. Male DR2-Tg mice underwent 60 min of intraluminal reversible middle cerebral artery occlusion (MCAO). RTL1000 or vehicle was injected 4, 6, or 8 h after MCAO, followed by three daily injections. In the single-dose study, one-time injection of RTL1000 was applied 4 h after MCAO. Cortical, striatal, and hemispheric infarct sizes were measured 24 or 96 h after stroke. Behavioral testing, including neuroscore evaluation, open field, paw preference, and novel object recognition, was performed up to 28 days after stroke. Our data showed that RTL1000 significantly reduced the infarct size 96 h after MCAO when the first injection was given at 4 and 6 h, but not 8 h, after the onset of stroke. A single dose of 400 or 100 μg RTL1000 also significantly reduced the infarct size 24 h after MCAO. Behavioral testing showed that RTL1000 treatment used 4 h after MCAO improved long-term cognitive outcome 28 days after stroke. Taken together, RTL1000 protects against acute injury if applied within a 6-h time window and improves long-term functional recovery after experimental stroke in DR2-Tg mice.